Note: Descriptions are shown in the official language in which they were submitted.
CA 0222l263 l997-ll-l7
WO 96/40139 PCT/US9G~'~,S G92
NOVEL FORMULATIONS FOR
TRANSDERMAL DELIVERY OF PERGDLIDE
FIELD OF INVENTION
This invention relates to the safe and efficacious transdermal
administration of pergolide for, among other things, the treatment of
Parkinson's Disease. More particularly, the invention relates to novel
methods, compositions, and devices for administering pergolide to a subject
10 through a body surface or memL.r~l ~e over a sustained time period. A
preferred embodiment is directed to the transdermal co-administration of a
pharmaceutically acceptable salt of pergolide in combination with a
permeation enhancer.
BACKGROUND OF THE INVENTION
Pergolide, 8-[(methylthio)methyl]-6-propylergoline, a compound based
on the ergoline ring system, is reported to be a dopaminergic agonist that
also decreases plasma prolactin concentrations. When used for treating
20 Parkinson's Disease, pergolide is used as a conjunctive therapy with
levodopa.
US Patent No. 4,166,182, incorporated herein in its entirety by
referel ,ce, describes the preparation of pergolide and its oral or parenteral
administration as a prolactin inhibitor and in the treatment of Parkinson's
25 Disease.
German patent application DE 4240798, incorporated herein its
entirety by reference, describes a pharmaceutical composition containing
ergot derivatives, including pergolide, for protection of nerves. The
composition may be delivered orally, sublingually, parenterally,
30 percutaneously or nasally.
CA 0222l263 l997-ll-l7
WO 96/40139 PCT~S~6/0~6~2
US Patent No. 4,797,405 incorporated herein in its entirety by
~eference, discusses stabilized pergolide oral compositions that demonstrate
reduced decomposition when exposed to light.
The dopaminergic agonist effect of pergolide has resulted in its use in
5 a variety of treatments, in addition to the treatment of Parkinson's Disease.
For example, US Patent No. 4,800,204, incorporated herein in its entirety by
reference, rliscusses a method of controlling tob~cco use by orally or
parenterally administering a direct dopamine receptor agonist such as
pergolide.
US Patent No. 4,935,429, incorporated herein in its entirety by
reference, discusses a method of treating psychostimulant abuse by orally or
parenterally administering a dopamine agonist such as pergolide.
US Patent No. 5,063,234, incorporated herein in its entirety by
reference, discusses a method of inhibiting bone demineralization by
15 administering, preferably orally, an ergot derivative, such as pergolide.
The oral administration of pergolide in the treatment of Parkinson's
Disease is initiated with 0.05 mg/day dosage for the first 2 days. The dosage
is then gradually increased by 0.1 or 0.15 mg/day every third day over the
next 12 days of therapy. The dosage may then be increased by 0.25 mg/day
20 every third day until an optimum therapeutic dosage is achieved at a range ofabout 1.5 to 8.0 mg/day. Generally, the daily dose is divided into three oral
doses. The side effects of oral administration include, but are not limited to
nausea, vomiting, diziness and orthostatic hypotension.
The transdermal route of parenteral delivery of drugs and other
25 biologically active agents ("agents") has been proposed for a wide variety ofsystemically acting and locally acting agents on either a rate-controlled or
non-rate-controlled basis and is described in numerous technical publications
such as the following: US Patents 3,598,122; 3,598,123; 3,731,683;
3,797,494; 4,031,894; 4,201,211; 4,286,592; 4,314,557; 4,379,454;
30 4,435,180; 4,559,222; 4,568,343; 4,573,995; 4,588,580; 4,645,502;
4,704,282; 4,788,062; 4,816,258; 4,849,226; 4,908,027; 4,943,435; and
CA 0222l263 l997-ll-l7
WC~ 96~4al39 PCT/US96/09692
5,004,610, the disclosures of which are incorporated in their entirety herein
b~ .-eference. The transdermal administration of a related compound,
lisuride, for treating Parkinson's Disease, is disclosed in US Patents
5,252,335 and 5,229,129, the disclosures of which are incorporated in their
~ 5 entirety herein by reference.
When first investigated in depth in the late 1960's, the transdermal
route of administration appeared to offer many advantages, particularly with
respect to agents that had short half lives and therefore required frequent,
repeated dosing or were subject to a high degree of first-pass metabolism by
the liver when orally administered. The peaks and valleys in blood
concentration resulting frorn frequent periodic doses of short half-life agents
would be eliminated and replaced by substantially constant plasma
conce, ~ lion. This would not only improve individual compliance but also
would eliminate the alternating periods of high side-effects and ineffective
blood conce, Ill ~lions associated with period dosing. Administering the agent
through the skin directly into the blood stream would also eliminate first-pass
metabolism of orally administered agents.
It was initially assumed, theoretically, that any short half-life agent of
high ~o~e".;~/ and skin permeability would be suitable for safe and eflective
transdermal administration. This assumption, however, has not been proven
true.
The failure of the transdermal route to fulfill the initial expectations of
its potential as an administrative portal was primarily due to the incredible
variety of properties with which nature has endowed the skin to permit it to
perform its function as the primary barrier to prevent the ingress of foreign
substances into the body. See Transdermal Drug Delivery: Problems and
Possibilities, B. M. Knepp, et al, CRC Critical Reviews and Therapeutic Drug
Carrier Systems, Vol. 4, Issue 1 (1987).
~ Thus, the transdermal route of administration, rather than being
30 available to every short half-life agent of high potency and skin permeability,
was found to be available only to those few agents that possess the proper
CA 02221263 1997-11-17
WO 96/40139 PCT/US96/09692
combination of a host of characteristics, most of which are unpredictable,
req~ired to render the agent suitable for safe and effective transdermal
administration.
The most significant of these characteristics are the following:
1. Skin Permeabilitv. The permeability of the skin to the agent
must be sufficiently high so that the agent can be administered at a
therapeutically effective rate through an area of skin no greater than about
200 cm2 and preferably no greater than 50 cm2. The person-to-person
variation in skin permeability at similar sites should also be considered.
2. Skin Bindin~. The skin beneath the transdermal delivery device
has the capability of creating a skin depot of drug by absorbing, adsorbing, or
binding a certain amount of agent. The amount of agent so bound must be
supplied to the skin before the agent can be delivered into the blood stream
at steady, therapeutically eflective rates. If large amounts of the agent are
bound in the skin, significant delays in the onset of therapeutic effect ("lag
time") will be observed together with corresponding delays and termination of
effect upon removal of the device. The potential also exists for toxic
quantities of potent agents to be contained within the skin beneath the
device. Skin binding is not related to skin permeability. Agents that are
highly permeable may also be highly bound causing a lag time sufficiently
long as to render them unsuitable for their intended use.
3. Irritation. The skin reacts to many topically applied substances,
particularly those maintained under occlusion, by blistering or reddening
accompanied by unpleasant burning, itching, and stinging sensations.
Animal models are used to screen for irritation. Animal models, however,
often produce both false positives and false negatives. There is also a wide
interpersonal variation in susceptibility to irritation. An agent must be
minimally irritating in a large percentage of the potential individual population
in order to be suitable for safe and effective transdermal administration.
4. Sensitization. Sensitization is an allergicreaction which is
induced when an agent is first applied to the skin and is elicited upon
CA 02221263 1997-11-17
WO 96/40139 PCT/US~6/0~16~2
continued exposure which may occur immediately or after a long period of
seemingly harmless exposure.
The sensitization may be local, elicited by topical exposure, which
manifests itself as contact dermatitis accompanied by blistering, itching,
5 reddening and burning at the site of application. More seriously, the
sensitization may be systemic, elicited by topical application but manifesting
itself by more general allergic reactions at sites other than the site of
application. Most seriously, the systemic sensitization may be elicited by oral
or intravenous administration of the drug. If the latter occurs, the individual
10 will be unable to take the drug by any route of administration.
Animal models are used to screen for sensitization. Animal models,
however, produce both false positives and false negatives. There is also a
wide variation in the allergic reaction between individuals as well as between
sexes, races and skin types. It is obvious that a useful transdermal agent
15 must be minimally sensitizing in a large pel ce"tage of the potential individual
population.
5. Pharmacokinetic ProPerties. The half-life of an agent is the
time after administration that half of the amount administered has been
eliminated from the body. Bec~use blood conce~ lions of continuously
20 administered agents will continue to increase for approximately six half-lives
before steady-state constant blood conce, Ill alions are achieved, an agent
must have a relatively short half-life to be suitable for continuous transdermaladministration. The transdermal half-lives of most agents have not been
determined. When half-lives of agents determined from intravenous
25 administration are compared with half-lives determined from transdermal
administration, the transdermal half-lives are generally longer but there can
be wide variation in half-life between individuals based upon factors such as
age, sex, health, and body type.
6. Pharmacodvnamic Properties. Constant blood levels may not
30 produce the desired therapeutic effects. For example, a therapeutic effect
may only be observed at peak blood concentration obtained from bolus
CA 02221263 1997-11-17
WO 96/40139 PCT/US96/09692
dosing but the peak concentration cannot be maintained because of side
e~fects associated therewith. Also, continuous administration of many agents
produces tolerance that may require either some agent-free interval or
continually increasing and therefore potentially hazardous doses of the
agent.
7. Potencv. Although a certain degree of potency is required for
transdermally administered agent to be effective, it is also possible for an
agent to be too potent. As potency increases, lower blood concentrations are
required and much smaller quantities are administered. Because of normal
inter-individual variations and skin permeability, it may not be possible to
precisely control whether a individual is receiving 1 ~lg/hr or 2 ,ug/hr, for
example. For a highly potent agent, a 1 llg/hr administration may be totally
ineffective and a 2 ,ug/hr rate fatal. Thus, the therapeutic index of an agent,
which is the ratio of toxic blood concentration to the therapeutic blood
concentration, becomes extremely significant. A highly potent agent should
also have a relatively wide therapeutic window in order to be suitable for
transdermal administration.
8. Metabolism. One of the perceived advantages of transdermal
administration was that it avoided the "first-pass" metabolism of the agent by
the liver that is associated with oral administration. It has now been
recognized, however, that the skin is also a large metabolizing organ in the
body for some drugs. Thus, although first-pass metabolism that occurs after
an orally administered agent enters the blood stream can be avoided, skin
metabolism, which occurs before the agent enters the bloodstream, cannot be
avoided. Skin metabolism is capable of creating metabolites that are inert,
irritating, toxic, or comparable in biological activity to that of the agent. Anagent, to be suitable for transdermal administration, must have the metabolic
properties that are consistent with its therapeutic use on continuous
administration.
The above summarizes the primary characteristics that effect suitability
of an agent for transdermal administration that have been recognized to date.
CA 0222l263 l997-ll-l7
WO 96/40~39 PCT/US~6/'W6~>2
There are undoubtedly others, some of which have not yet been recognized
ar~d, in order for an agent to be suitable for transderma~ administration, it
must possess the right combination of all these characteristics, a combination
of which, as illustrated by the very few drugs that are now suitable for
- ~ administration from transdermal delivery devices, is quite rare and unpredictable.
SUMMARY OF THE INVENTION
It is unexpected that pergolide would be delivered through the skin at
meaningful therapeutic rates either as a base or salt because, as its chemical
name 8-[(methylthiolmethyl]-6-propylergoline monomethanesulfonate)]
indicates, it has a complex chemical structure which does not lend itself to
readily permeate through biological membranes such as the skin.
Furthermore, it is even more unexpected that transdermal dosage forms
provided with a pharmaceutically acceptable salt form of pergolide would
result in a greater pergolide flux through skin than dosage forms provided
with pergolide free base.
Nonetheless, according to this invention, it has been discovered that
20 pergolide can be safely and efficaciously administered transdermally to
provide, among other things, treatment for Parkinson's Disease, with a
reduced incidence of side eflects and improved individual compliance. In
addition, the present invention provides methods for the transdermal delivery
of pergolide and delivery systems for effecting the same, which are suitable
25 for the administration of pergolide continuously through a body surface or
membrane to achieve and maintain therapeutic blood plasma levels of
pergolide in an individual. A particularly advantageous aspect of this
invention is the ability to maintain substantially constant blood plasma levels
- of pergolide in an individual over extended periods of time.
Surprisingly, the inventors have discovered that transdermal dosage
forms provided with a pharmaceutically acceptable salt form of pergolide
CA 02221263 1997-11-17
WO 96/40139 PCT/US96/09692
result in a greater pergolide flux through skin than dosage forms provided
v~Jith pergolide free base. This is contrary to findings of-a substantial amountof the prior art wherein for a majority of agents which have been tested for
transdermal administration, it is recognized in the art that the permeability of5 the skin to the unioinized form of the drug is generally substantially greaterthan that of the ionized form. A pr~rer, ed embodiment is therefore directed to
providing the reservoir of a transdermal delivery device with a
pharmaceutically acceptable salt of pergolide, pl ererably pergolide mesylate,
together with a permeation enhancer.
As used herein, the term "transdermal" intends percutaneous and
transmucosal administration, ie, passage of pergolide through intact
unbroken skin or mucosal tissue into the systemic circulation.
As used herein, the term "pergolide" intends not only the basic form of
pergolide but also pharmaceutically acceptable salt forms of pergolide.
As used herein the term "salt" intends, but is not limited to,
pharmaceutically acceplable salts such as chlorides, acetates, sulfates,
phosphates, and mesylates.
As used herein, the term "pergolide therapy" intends all medical
conditions for which pergolide is or will be indicated, including, without
20 limitation, as a psychic energizer and in the treatment of Parkinson's Disease,
migraine, allergic responses, urticaria, hypertension, endometritis, and other
conditions associated with dopaminergic agonists.
As used herein, the term "individual" intends a living mammal and
includes, without limitation, humans and other primates, livestock and sports
25 animals such as cattle, pigs and horses, and pets such as cats and dogs.
As used herein, the term "therapeutic blood plasma level" intends the
level of pergolide in blood plasma that achieves a therapeutic effect and is
typically within the range of about 100 pg/mL - 2000 pg/mL.
As used herein, the term "therapeutically effective rate" intends a rate
30 of pergolide delivery effective to achieve therapeutic blood plasma levels of pergolide in an individual during the administration period.
CA 02221263 1997-11-17
WO 96/40139 PCT/US9''.~gb92
As used herein, the phrase "sustained time period" or "administration
period" intends at least about 8 hours and will typically intend a period in therange of about one to about seven days.
As used herein, the phrase "predetermined area of skin" intends a
5 defined area of intact unbroken skin or mucosal tissue. That area will usually be in the range of about 1 cm2 to about 100 cm2.
As used herein, the term "permeation enhancer" intends an agent or a
mixture of agents which increases the permeability of the skin to pergolide.
As used herein, the term "permeation enhancement" intends an
10 increase in the permeability of skin to pergolide in the presence of a
permeation enhancer as compared to permeability of skin to pergolide in the
absence of a permeation enhancer.
The present invention relates to compositions, devices and methods
for the transdermal administration of pergolide in the treatment of Parkinson's
15 Disease, among other things. According to the present invention, it has been
found that pergolide may be safely and efficaciously administered
transdermally through a body surface or membrane at a therapeutically
effective rate for a predetermined, sustained time period in order to provide
an effective therapeutic result. Another aspect of the present invention is
20 directed to the transdermal administration of pergolide together with a
suitable permeation enhancer or mixture of enhancers.
The system of the invention comprises a carrier or matrix adapted to
be placed in pergolide or pergolide- and permeation enhancer- transmitting
relation to the selected skin or other body site. The carrier or matrix contains25 sufficient amounts of pergolide to continuously administer pergolide to the
site at a therapeutically effective rate during an administration period. In
another embodiment, the carrier or matrix contains sufficient amounts of
pergolide and a permeation enhancer to continuously coadminister pergolide
at a therapeutically effective rate to the site together with the permeation
30 enhancer during the administration period.
CA 02221263 1997-11-17
WO 96/40139 PCT/US96/0~ 2
The accompanying figures, which are incorporated in and constitute a
par~. of this specification, illustrate embodiments of the invention and, together
with the description serve to explain the principles of the invention.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 is a cross-section through a schematic perspective view of
one embodiment of a transdermal therapeutic system according to this
invention prior to application to the skin.
Figure 2 is a cross-section view through another embodiment of this
invention.
Figure 3 is a cross-section view through another embodiment of this
invention.
Figure 4 is a cross-section view through another embodiment of this
15 invention.
Figure 5 is a graph of the flux of pergolide base through human
epidermis, in vitro, at 35~C, from various aqueous and non-aqueous donors.
Figure 6 is a graph of the flux of pergolide mesylate through human
epidermis, in vitro, at 35~C, from various aqueous and non-aqueous donors.
Figure 7 is a graph of the cumulative release of pergolide base
through human epidermis at 35~C, in vitro from an EVA matrix system with
various permeation enhancers.
Figure 8 is a graph of the cumulative release of pergolide mesylate
through human epidermis at 35~C, in vitro, from an EVA matrix system with
25 various permeation enhancers.
Figure 9 is a graph of the cumulative release of pergolide base
through human epidermis at 35~C in vitro, from an EVA matrix system with
various permeation enhancers.
Figure 10 is a graph of the cumulative release of pergolide mesylate
30 through human epidermis at 35~C, in vitro, from an EVA matrix system with
various permeation enhancers.
-
CA 02221263 1997-11-17
WO 96/40139 PCT/US96/09692
11
Figure 11 is a graph of the cumulative release of pergolide base
through human epidermis in vitro at 35~C, from an EtOH system having an
EVA (1 8%vinyl acetate) rate controlling membrane with various permeation
enhancers and a polyisobutylene/mineral oil based in-line contact adhesive
preloaded with drug.
Figure 12 is a graph of the cumulative release of pergolide mesylate
through human epidermis, in vitro, at 35~C, from an EtOH system having an
EVA (18% vinyl acetate) rate controlling membrane with various permeation
enhancers and a polyisobutylene / mineral oil based in-line contact adhesive
10 preloaded with drug.
Figure 13 is a graph of the flux of pergolide base through human
epidermis, in vitro, at 35~C, from an EtOH system having an EVA (28% vinyl
acetate) rate controlling merllbrdlle with various permeation enhancers and a
polyisobutylene/mineral oil based in-line contact adhesive preloaded with
15 drug.
Figure 14 is a graph of the flux of pergolide mesylate through human
epidermis, in vitro, at 35~C, from an EtOH system having an EVA (28% vinyl
acetate) rate controlling membrane with various permeation enhancers and a
polyisobutylene/mineral oil based in-line contact adhesive preloaded with
20 drug.
Figure 15 is a graph of the flux of pergolide mesylate through human
epidermis, in vitro, at 35~C, from various pergolide mesylate/GML/methyl
laurate/EVA 40 systems with no adhesive.
Figure 16 is a graph of the flux of pergolide mesylate through human
25 epidermis, in vitro, at 35~C, from various pergolide mesylate/GML/dodecyl
acetate/EVA 40 systems with no adhesive.
Figure 17 is a graph of the flux of pergolide mesylate through human
epidermis, in vitro, at 35~C, from various pergolide mesylatelGML/lauryl
Iactate/EVA 40 systems with no adhesive.
Figure 18 is a graph of the flux comparison of GML coenhancers
methyl laurate, lauryl lactate, and dodecyl acetate in combination with mineral
CA 02221263 1997-11-17
WO 96/40139 PCT/US96/0~692
12
oil through human epidermis, in vitro, at 35~C, from various pergolide
mè~ylate/GML/coenhancer/mineral oil/EVA 40 systems with no adhesive.
DETAILED DESCRIPTION OF THE INVENTION
Accoruing to the present invention, it has been found that pergolide
may be administered to the human body at a therapeutically effective rate via
the transdermal route for the purpose of treating Parkinson's Disease, among
other things, when administered alone or coadministered with a suitable
permeation enhancer. Therapeutic blood plasma levels of 100 pg/mL to 2000
pg/mL can be achieved according to this invention. Representative in vitro
skin fluxes of pergolide through human skin are in the range of 0.1 - 8.0
,lg/cm2 hr, depending on the form of pergolide (base or salt), the permeation
enhancer, and whether an in-line contact adhesive was present in the path of
15 drug flow. According to this invention, it is ,~rererable to administer pergolide
at a flux of at least about 1.0 tlg/cm2 hr.
It is estimated that therapeutic blood plasma levels can be achieved
within approximately 5 to 10 hours following application of the first patch.
When a subsequent system is applied, a lag period of no pergolide delivery
20 iS not experienced due to the presence of a skin depot of pergolide remainingfrom the prior system, thus pergolide is continuously administered throughout
subsequent system applications in order to maintain therapeutic blood
plasma levels of pergolide over a sustained time period. The system is easily
adapted for shorter or longer duration treatments, but generally 72 hours is
25 the preferred duration for a single treatment.
The desired pergolide admininstration rate may be achieved by
increasing or decreasing the surface area of the transdermal delivery device
without effecting the flux. For example, for a pergolide skin flux of 1.1 ,ug/cmZ
hr, a patch having a surface area of about 60 cm2 would deliver
30 approximately 1.6 mg of pergolide over a 24 hour period.
CA 02221263 1997-11-17
WO 96/40139 PCT/US~)~J096~2
13
The pergolide administration rate may also be increased by
inereasing the flux of pergolide through skin by the use of permeation
enhancers which include, but are not limited to: monoglycerides such as
glycerol monolaurate, glycerol monooleate or glycerol monolinoleate, lactate
esters such as lauryl lactate, methyl laurate, caproyl lactic acid, lauramide
diethanolamine (LDEA), dimethyl lauramide, polyethylene glycol~ lauryl
ether (Laureth-4), and ethanol, aione or in combinations of one or more. An
embodiment of this invention also relates to codelivery of at least one of the
permeation enhancers mentioned above to aid in the transdermal delivery of
pergolide.
The present inventors also found that certain adhesives were preferred
as the in-line contact adhesive when one was used in a therapeutic
transdermal pergolide system. More particularly, it was found that systems
using polyisobutylene adhesives as the in-line contact adhesive resulted in
greater flux of pergolide through skin than when other adhesives, such as
acrylate adhesives, were used.
Therefore, the present invention, in one embodiment, is directed to a
composition of matter for administration to a body surface or membrane to
deliver pergolide by permeation through the body surface or membrane at a
therapeutically effective rate, wherein the composition comprises an amount
of pergolide in a carrier effective to permit sustained release of pergolide at a
therapeutically effective rate over an administration period of at least about 8hours, wherein said therapeutically effective rate of pergolide release
achieves therapeutic blood plasma levels of pergolide in an individual.
Another embodiment is directed to a composition of matter for
administration to a body surface or ~,er~brane to deliver pergolide by
permeation through the body surface or membrane at a therapeutically
effective rate, wherein the composition comprises, in combination:
(a) a therapeutically effective amount of pergolide; and
30 (b) a permeation-enhancing amount of a permeation enhancer.
CA 0222l263 l997-ll-l7
WO 96/40139 PCT/US96/09692
14
The drug may be present in the composition in an amount ranging from
0.1 -to 20% by weight.
This invention finds particular usefulness in administering pergolide
across skin. It is also useful, however, in administering pergolide across
mucosa. According to our invention, pergolide with or without a permeation
enhancer are placed in drug or drug and permeation enhancer- transmitting
relationship to an appropriate body surface, prererably in a pharmaceuticaliy
acceptable carrier thereof, and maintained in place for the desired
administration period.
0 The pergolide and the permeation enhancer, if used, are typically
dispersed within a physiologically compatible matrix or carrier, as more fully
described below, which may be applied directly to the body as an ointment,
gel, cream, suppository or sublingual or buccal tablet. When used in the form
of a liquid, ointment, lotion, cream or gel applied directly to the skin, it is
preferable, although not required, to occlude the site of administration. Such
compositions can also contain other permeation enhancers, stabilizers, dyes,
diluents, pigments, vehicles, inert fillers, excipients, gelling agents,
vasoconstrictors, and other components of topical compositions as are known
to the art.
In other embodiments, the pergolide with or without the permeation
enhancer would be administered from a transdermal device as more fully
described below. Examples of suitable transdermal delivery devices are
illustrated in Figs. 1 - 4. In the figures, the same reference numbers are used
throughout the different figures to designate the same or similar components.
25 The figures are not drawn to scale.
Referring now to Figure 1, a preferred embodiment of a transdermal
therapeutic system according to this invention comprises transdermal delivery
deviGe 10 comprising a reservoir 12, preferably in the form of a matrix
containing pergolide and a permeation enhancer, if used, dispersed therein.
30 Reservoir 12 is sandwiched between a backing 14 and an in-line contact
adhesive layer 16. The device 10 adheres to the surface of the skin 18 by
CA 02221263 1997-11-17
WO 96~40139 PCT/US96f~3~12
means of the adhesive layer 16. The adhesive layer 16 may optionally
cofl~ain the permeation enhancer and/or pergolide. A strippable release liner
(not shown in FIG.1) is normally provided along the exposed surface of
adhesive layer 16 and is removed prior to application of device 10 to the skin
5 18. Optionally, a rate-controlling membrane (not shown) may be present
between the reservoir 12 and the adhesive layer 16. Although the preferred
embodiments of this invention utilize an in-line adhesive as is shown in
Figure 1, other means for maintaining the system on the skin can be
employed. Such means include a peripheral ring of adhesive outside the
10 path of the drug from the system to the skin or the use of other fastening
means such as buckles, belts, and elastic arm bands.
Alternatively, as shown in FIG. 2, transdermal therapeutic device 20
may be allacl ,ed to the skin or mucosa of a individual by means of an
adhesive overlay 22. Device 20 is comprised of reservoir 12, preferably in
15 the form of a matrix c~nlai"ing pergolide and a permeation enhancer, if used,dispersed therein. A backing layer 14 is provided adjacent one surface of
reservoir 12. Adhesive overlay 22 maintains the device on the skin and may
be fabricated together with, or provided separately from, the remaining
elements of the device. With certain formulations, the adhesive overlay 22
20 may be preferable to the in-line contact adhesive 16 as shown in FIG.1.
Backing layer 14 is preferably slightly larger than reservoir 12, and in this
manner prevents the materials in reservoir 12 from adversely interacting with
the adhesive in overlay 22. Optionally, a rate-controlling membrane (not
shown in FIG. 2) may be provided on the skin-proximal side of reservoir 12.
25 A strippable release liner 24 is also provided with device 20 and is removed
just prior to application of device 20 to the skin.
In FIG. 3, transdermal delivery device 30 comprises a pergolide and
permeation enhancer reservoir ("pergolide reservoir") 12 substantially as
described with respect to FIG.1. Permeation enhancer reservoir ("enhancer
30 reservoir") 26 comprises the permeation enhancer dispersed throughout and
contains pergolide at or below saturation, when in equilibrium with the first
CA 0222l263 l997-ll-l7
WO 96/40139 PCT~S96/09692
16
reservoir. Enhancer reservoir 26 is preferably made from substantially the
same matrix as is used to form pergolide reservoir 12. A rate-controlling
membrane 28 for controlling the release rate of the permeation enhancer
from enhancer reservoir 26 to pergolide reservoir 12 is placed between the
5 two reservoirs. A rate-controlling membrane (not shown in FIG. 3) for
controlling the release rate of the enhancer from pergolide reservoir 12 to the
skin may also optionally be utilized and would be present between adhesive
layer 16 and reservoir 12.
The rate-controlling membrane may be fabricated from permeable,
10 semipermeable or microporous materials which are known in the art to control
the rate of agents into and out of delivery devices and having a permeability
to the permeation enhancer lower than that of drug reservoir 12. Suitable
materials include, but are not limited to, polyethylene, polyvinyl acetate,
ethylene n-butyl acetate and ethylene vinyl acetate copolymers.
Superimposed over the permeation enhancer reservoir 26 of device 30
is a backing 14. On the skin-proximal side of reservoir 12 are an adhesive
layer 16 and a strippable liner 24 which would be removed prior to application
of the device 30 to the skin.
In the embodiments of FIGS. 1, 2 and 3, the carrier or matrix material
20 of the reservoirs has sufficient viscosity to maintain its shape without oozing
or flowing. If, however, the matrix or carrier is a low-viscosity flowable
material such as a liquid or a gel, the composition can be fully enclosed in a
pouch or pocket, as known to the art from US Pat. No. 4,379,454 (noted
above), for example, and as illustrated in FIG. 4. Device 40 shown in FIG. 4
25 comprises a backing member 14 which serves as a protective cover for the
device, imparts structural support, and substantially keeps components in
device 40 from escaping the device. Device 40 also includes reservoir 12,
which contains the pergolide with or without a permeation enhancer, and
bears on its surface distant from backing member 14, a rate-controlling
30 membrane 28 for controlling the release of pergolide and/or permeation
enhancer from device 40. The outer edges of backing member 14 overlay
CA 02221263 1997-11-17
WO 96/40139 PCT~US96/0!~692
17
the edges of reservoir 12 and are joined along the perimeter with the outer
e~es of the rate-controlling membrane 28 in a fluid-tight arrangement. This
sealed reservoir may be effected by pressure, fusion, adhesion, an adhesive
applied to the edges, or other methods known in the art. In this manner,
5 reservoir 12 is contained wholly between backing member 14 and rate-
controlling membrane 28. On the skin-proximal side of rate-controlling
membrane 28 are an adhesive layer 16 and a strippable liner 24 which would
be removed prior to application of the device 40 to the skin.
In an alternative embodiment of device 40 of FIG. 4, reservoir 12
10 contains the permeation enhancer and contains pergolide at or below
saturation. The pergolide and an additional amount of permeation enhancer
are present in adhesive layer 16, which acts as a se,ua~dle reservoir.
The pergolide with or without the permeation enhancer can be
administered to human skin or mucosa by direct application to the skin or
15 mucosa in the form of an ointment, gel, cream or lotion, for example, but arepreferably administered from a skin patch or other known transdermal
delivery device which contains a saturated or unsaturated formulation of the
pergolide or pergolide and enhancer. The formulation may be aqueous or
non-aqueous based. The formulation should be designed to deliver the
20 pergolide at the necessary fluxes. Aqueous formulations typically comprise
water or water/ethanol and about 1-5 wt% of a gelling agent, an example
being a hydrophilic polymer such as hydroxyethylcellulose or
hydroxypropylcellulose. Typical non-aqueous gels are comprised of silicone
fluid or mineral oil. Mineral oil-based gels also typically contain 1-2 wt% of a25 gelling agent such as colloidal silicon dioxide. The suitability of a particular
gel depends upon the compatibility of its constituents with the drug and the
permeation-enhancing mixture, if used, in addition to any other components
in the formulation.
~ The reservoir matrix should be compatible with pergolide, the
30 permeation enhancer, and any carrier therefor. The term "matrix" as used
herein refers to a well-mixed composite of ingredients fixed into shape.
CA 02221263 1997-11-17
WO 96/40139 PCT/IJ5,G~1~3G92
18
When using an aqueous-based formulation, the reservoir matrix is preferably
a hydrophilic polymer, eg7 a hydrogel.
When using a non-aqueous based formulation, the reservoir matrix is
pr~:r~rably composed of a hydrophobic polymer. Suitable polymeric matrices
5 are well known in the transdermal drug delivery art, and examples are listed
in the above-named patents previously incorporated herein by reference; A
typical laminated system would consist essentially of a polymeric membrane
and/or matrix such as ethylene vinyl acetale (EVA) copolymers, such as
those described in US Pat. No. 4,144,317, preferably having a vinyl acetate
10 (VA) content in the range of from about 9% up to about 60% and more
preferably about 9% to 40% VA. Polyisobutylene/oil polymers containing
from 4-25% high molecular weight polyisobutylene and 20-81% low molecular
weight polyisobutylene with the balance being an oil such as mineral oil or
polybutene may also be used as the matrix material.
The amount of pergolide present in the therapeutic device and
required to achieve an effective therapeutic result depends on many factors,
such as the minimum necessary dosage of the pergolide for the particular
indication being treated; the solubility and permeability of the matrix, taking
into account the presence of a permeation enhancer, of the adhesive layer
20 and of the rate-controlling membrane, if present; and the period of time for
which the device will be fixed to the skin. The minimum amount of pergolide
is determined by the requirement that sufficient quantities of pergolide must
be present in the device to maintain the desired rate of release over the given
. period of application. The maximum amount for safety purposes is
25 determined by the requirement that the quantity of pergolide present cannot
exceed a rate of release that reaches toxic levels.
The pergolide is normally present in the matrix or carrier at a
concentration in excess of saturation, the amount of excess being a function
of the desired length of the delivery period of the system. Pergolide may,
30 however, be present at a level below saturation without departing from this
invention as long as it is continuously administered to the skin or mucosal site
CA 02221263 1997-11-17
WO 96/40139 PCT/US~7G/~g6~1Z
19
at a therapeutic rate and for a period of time sufficient to deliver a
theFapeutically effective amount of pergolide that provides the desired
therapeutic result.
The permeation enhancer useful in the present invention is selected
5 from those compounds which are compatible with pergolide and which
provide enhanced skin permeation to the drug when it is administered
together with the drug to the skin of a user. Additionally, the permeation
enhancer must not adversely interact with the adhesive of the in-line conla~;l
adhesive layer if one is present. Such permeation enhancers can be
10 selected from, but are not limited to, C2 4 alcohols such as ethanol and
isopropanol, polyethylene glycol monolaurate, laureth4, lactate esters such
as lauryl lactate, dimethyl lauramide, LDEA, caproyl lactic acid, esters of fatty
acids having from about 10 to about 20 carbon atoms such as methyl laurate,
and monoglycerides or mixtures of monoglycerides of fatty acids alone, or in
5 combinations with each other.
A prerer, ed permeation enhancer according to this invention
comprises glycerol monolaurate and methyl laurate. Methyl laurate has been
found to be particularly desirable as it is obtainable at a high degree of purity,
thus providing a purer and better defined permeation enhancer and a system
20 which is more readily characterized. Additionally, the inventors have found
that the addition of mineral oil to the pergolide reservoir comprising glycerol
monolaurate and methyl laurate provides a surprising and synergistic effect
to the pergolide skin flux. In a particularly preferred embodiment, the ratio ofglycerol monolaurate / methyl laurate / mineral oil is .75 /1.0 / .50. As used
25 herein, "mineral oil" refers to a mixture of liquid hydrocarbons of petroleum.
Polybutene may also be substituted for the mineral oil.
Typically, monoglycerides have been available as a mixture of
monoglycerides of fatty acids with one monoglyceride being the principal
component, from which component the mixture derives its name. For
30 example, one commercial monoglyceride is Emerest 2421 glycerol
monooleate (Emery Division, Quantum Chemical Corp.), which is a mixture of
CA 0222l263 l997-ll-l7
WO 96/40139 PCT/USg6 05692
glycerol oleates with a glycerol monooleate content of 58% and a total
mGnoesters content of 58%. Other examples of commercial monoglycerides
are Myverol 1 899K glycerol monooleate (Eastman Chemical Products) which
has a glycerol monooleate content of 61% and a total monoesters content of
93%, and Myverol 1 892K glycerol monolinoleate which has a glycerol
monolinoleate content of 68% and a minimum total monoesters content of
90%. The monoesters are chosen from those with from 10 to 20 carbon
atoms. The fatty acids may be saturated or unsaturated and include, for
example, lauric acid, myristic acid, stearic acid, oleic acid, linoleic acid andpalmiticacid. Monoglyceride permeation enhancers include glycerol
monooleate, glycerol monolaurate and glycerol monolinoleate, for example.
In a presently preferred embodiment of this invention, the permeation
enhancer comprises glycerol monolaurate as the monoglyceride.
It has been seen that glycerol monooleate having a total monoesters
content of less than about 65% interacts adversely with known adhesive
materials to such an extent that the adhesive cannot function to maintain a
delivery device on the skin. Therefore, when an in-line adhesive is present
as a part of the device of the invention so that a permeation enhancer must
pass through the adhesive, and when glycerol monooleate is utilized as the
permeation enhancer, the glycerol monooleate must have a total monoesters
content of at least 65%.
The permeation-enhancing mixture is dispersed through the matrix or
carrier, prererably at a conce, ~ lion sufficient to provide permeation-
enhancing amounts of enhancer in the reservoir throughout the anticipated
administration period. Where there is an additional, separate permeation
enhancer matrix layer as well, as in FIGS. 3 and 4, the permeation enhancer
normally is present in the separate reservoir in excess of saturation.
In addition to the pergolide and permeation enhancer, the matrix or
carrier may also contain dyes, pigments, inert fillers, excipients and other
conventional components of pharmaceutical products or transdermal devices
known to the art.
CA 02221263 1997-11-17
WO 96/40139 21 PCT/U596~09692
Because of the wide variation in skin permeability from individual to
ind,vidual and from site to site on the same body, it may be pr~ferable that
the pergolide, with or without a permeation enhancer, be administered from a
rate-controlled transdermal delivery device. Rate control can be obtained
5 either through a rate-controlling membra"e or adhesive or both as well as
through the other means.
A certain amount of pergolide will bind reversibly to the skin, and it is
accordingly prerer,ed that the skin-contacting layer of the device include this
amount of pergolide as a loading dose.
The surface area of the device of this invention can vary from about 1-
200 cm2. A typical device, however, will have a surface area within the range
of about 1-50 cm2, preferably about 20 cm2.
The devices of this invention can be designed to effectively deliver
pergolide for an extended time period of from several hours up to 7 days or
15 longer. Seven days is generally the maximum time limit for application of a
single device because the adverse effect of occlusion of a skin site increases
with time and the normal cycle of sloughing and replacement of the skin cells
occurs in about 7 days.
Preferably, the transdermal drug delivery device contains sufficient
20 amounts of a permeation enhancer as described above and pergolide, in
combination, to provide systemic administration of pergolide through the skin
at a therapeutically effective rate during the administration period in order toprovide therapeutic blood plasma levels.
Preferably, a device for the transdermal administration of pergolide, at
25 a therapeutically effective rate, comprises:
(a) a reservoir comprising:
(i) 1-15% by weight pergolide,
(ii) 10-70% by weight of a permeation enhancer,
(iii) 35 to 85% by weight ethylene vinyl acetate having a vinyl
acetate content of 9-60%;
(b) a backing behind the skin-distal surface of the reservoir; and
CA 02221263 1997-11-17
WO 96/40139 PCT/US96/'0~692
22
(c) means for maintaining the reservoir in drug- and permeation
enhancer- transmitting relation with the skin.
More prererably, a device for the transdermal administration of
pergolide, at a therapeutically effective rate, comprises:
(a) a reservoir comprising:
(i) 1 to 15% by weight of a pharmaceutically acceptable salt
of pergolide,
(ii) 10 to 70% by weight of a permeation enhancer,
(iii) 45 to 85% by weight ethylene vinyl acetate having a vinyl
acetate content of 9-40%;
(b) a backing behind the skin-distal surface of the reservoir; and
(c) means for maintaining the reservoir in drug- and permeation
enhancer -transmitting relation with the skin.
Most preferably, a device for the transdermal administration of
5 pergolide, at a therapeutically effective rate, comprises:
(a) a reservoir comprising:
(i) 1 to 15% by weight pergolide mesylate,
(ii) 1-35% by weight glycerol monolaurate,
(iii) 1-35% by weight methyl laurate,
(iV) 1-35% by weight mineral oil,
(v) 45 to 80% by weight ethylene vinyl acetate having a vinyl
acetate content of 30-40%;
(b) a backing behind the skin-distal surface of the reservoir; and
(c) means for maintaining the reservoir in drug- and permeation
25 enhancer- transmitting relation with the skin.
The backing may be a breathable or occlusive material such as
polyethylene, polyurethane, polyester or ethylene vinyl acetate films. If
mineral oil is used, a polyester backing is preferred. If an ethylene vinyl
acetate is employed as the backing, preferably, it has an acetate content of
30 33% or 40%.
CA 02221263 1997-11-17
WO 96/40139 PCT/US~6~'~56~2
23
The means for maintaining the reservoir in drug and permeation
enhancer transmitting relation with the skin are pr~rer~l ly a polyisobutylene
adhesive, as described in the Examples that follow. A further embodiment of
the invention is directed to including in the adhesive a small percentage, eg,
- 5 from about 1.0 to about 5 wt% of pergolide.
The aforementioned patents describe a wide variety of materials which
can be used for fabricating various layers or components of the transdermal
pergolide delivery systems according to this invention. This invention,
therefore, contemplates the use of other materials other than those
~0 specifically disclosed herein including those which may become hereafter
known to the artist capable of forming the necessary functions.
The invention is also directed to a method of continuously
administering pergolide to a individual at a therapeutically effective rate
during an administration period in order to provide substantially constant
15 therapeutic blood plasma levels of pergolide in an individual.
Another method of the present invention is directed to a method for the
transdermal coadministration of pergolide at a therapeutically effective rate
together with a skin permeation-enhancing amount of a permeation enhancer
in order to achieve and maintain therapeutic blood plasma levels of pergolide
20 in an individual, comprising:
(a) coadministering to a body surface or membrane, pergolide; and
(b) a permeation enhancer, wherein pergolide is delivered at a
therapeutically effective rate during the administration period in order to
achieve and maintain therapeutic blood plasma levels of pergolide in an
25 individual. The pergolide and permeation enhancer may be administered to
the body surface or membrane by means of the devices and compositions
described above.
A preferred embodiment of the present invention comprises a method
of treating Parkinson's Disease. To be useful in treating Parkinson's
30 Disease, pergolide should be present above plasma concentrations of about
100 pg/mL, preferably at concentrations above about 300 pglmL and most
CA 0222l263 l997-ll-l7
WO 96/40139 PCT/US96/09692
24
preferably at concentrations of about 1000 pg/mL. To achieve this result,
p'ergolide is delivered at an estimated therapeutic rate of at least about 100
9 per hour, but typically of at least 125 ~lg/hr, and more typically at about
150 ~lg/hr, for the treatment period, usually about 12 hours to 7 days. For
5 example, a 20 cm2 system would require a pergolide flux through skin of 7.5
,ug/cm2 hr in order to achieve the desired therapeutic rate of 150 ,,lg/hr.
Alternatively, three 25 cm2 systems would require a pergolide flux of about 2
~g/cm2 hr to achieve the administration rate of 150 ~g/hr. Such regimens
would deliver approximately 3.6 mg of pergolide over a 24 hour period.
The length of time of pergolide presence and the total amount of
pergolide in the plasma can be changed following the teachings of this
invention to provide different treatment regimens. Thus, they can be
controlled by the amount of time during which exogenous pergolide is
delivered transdermally to an individual or animal.
Having thus generally described our invention, the following specific
examples describe preferred embodiments thereof but are not intended to
limit the invention in any manner.
EXAMPLE 1
Several test samples were made to measure the flux of pergolide
base and mesylate through human cadaver epidermis from donor vehicles
containing the pergolide base or mesylate mixed with water alone, water and
ethanol, or mineral oil alone as shown in Table 1. Transdermal fluxes were
25 obtained using human epidermis at 35~C in standard diffusion cells. Figures
5 and 6 graphically depict the results. As seen in these Figures, the average
baseline skin flux of pergolide base without any permeation enhancer is
approximately 0.3 ~g/cm2-hr over a fifty two hour period, while the average
baseline skin flux of pergolide mesylate without permeation enhancers is
30 approximately 1.1 )lg/cm2-hr over the same time period.
CA 0222l263 l997-ll-l7
WO 96/40139 25 PCT~U5~6~ )592
TABLE 1
- Aqueous and Non-Aqueous Donor Solutions (weight percent)
- reryolide H~O EtOH Minera! Oil
(form and content)
Base 2 98 0 0
Base 5 45 55 0
Base 5 70 30 0
Base 2 0 0 98
Mesylate2 98 0 0
Mesylate 5 45 55 0
Mesylate5 70 30 0
Mesylate2 0 0 98
EXAMPLE 2
The drug/permeation enhancer reservoirs were prepared by mixing ethylene
vinyl acetate having a vinyl acetate content of 40 percent ("EVA 40", USI
Chemicals, Illinois), with pergolide base or mesylate, GML (Grindsted
Products, Braband, Denmark) or LDEA (Lonza, Inc.), and mineral oil (Witco
10 Corp.). The mixture was then dissolved in tetrahydrofuran. After blending,
the mixture was hand cast and dried to a 5 mil. thick film. The composition of
the drug reservoirs is shown in Table 2.
CA 02221263 1997-11-17
WO 96/40139 PCT/US96/09692
26
- TABLE 2
Drug/Permeation Enhancer Reservoir Composition (weight percent)
Pergolide LDEA Glycerol Mineral EVA 40
Monolaurate Oil
(form and co~ "t)
Base 10 15 0 15 60
Base 10 0 20 14 56
Mesylate 10 15 0 15 60
Mesylate 10 0 20 14 56
The film was then laminated to a pigmented medium density
polyethylene/aluminum foil/PET/EVA (Medpart~)) backing on one side and an
acrylate contact adhesive on the opposite side (3M, St. Paul, MN). The
laminate was then punched down to an area of 1.6 cm2 .
Circular pieces of human epidermis were placed with stratum corneum
10 facing up. The release liner of the laminate was removed and the system
was ce"lered over the stratum corneum side of the epidermis. The edges of
epidermis were then folded around the system. This assembly was then
mounted on a Teflon rod. A known volume of receptor solution was then
placed in a test tube and was equilibrated at 35~C. The Teflon rod with
15 system and epidermis attached was then placed in a water bath at 35~C.
Mixing was accomplished by attachment to a motor which caused constant
vertical mixing.
At given time intervals, the entire receptor solution was removed from
the test tubes and replaced with an equal volume of fresh receptor solutions
20 previously equilibrated at 35~C. The receptor solutions are stored in capped
vials at room temperature until assayed for pergolide content by HPLC. From
the drug conce, Ill clion and the volume of the receptor solutions, the area of
permeation and the time interval, the flux of the drug through the epidermis
CA 02221263 1997-11-17
WO 96/40139 PCT/US91~ '0~6~2
27
was calculated as follows: (drug concentration X volume of receptor)/(area x
tirhe) = flux (,lg/cm2-hr). The cumulative release of the pergolide base or
mesylate is shown in Figures 7 and 8.
EXAMPLE 3
The drug/permeation enhancer reservoirs were prepared accor.liny to
Example 2. The film was then laminated to Medpar backing on one side and
a polyisobutylene adhesive containing 2.5% by weight of pergolide on the
other. The adhesive was prepared by dissolving 19.8% 1.2M
polyisobutylene, 24.7% 35K polyisobutylene and 55.5% light mineral oil in
heptane. The 2.5% pergolide was added and the entire mixture was cast to a
dry thickness of 2 mils. The film was then cut into circles using a stainless
steel punch with an area of 1.6 cm2.
The epidermis was separated from the dermis of the skin donor after
immersion in 60~C water for 60 seconds. Discs (7/8-inch diameter) were cut
from the epidermis, and the discs were kept at 4~C in a hydrated state until
they were used.
For each device tested, the release liner was removed and the drug-
releasing surface was placed against the stratum corneum side of a disc of
epidermis which had been blotted dry just prior to use. The excess epidermis
was wrapped around the device so that none of the device edge was
exposed to the receptor solution. The device covered with epidermis was
attached to the flat side of the Teflon holder of a release rate rod using nylonnetting and nickel wire. The rods were reciprocated in a fixed volume of
receptor solution. The entire receptor solution was changed at each
~ sampling time. The temperature of the receptor solution in the water bath
was maintained at 35~C. The cumulative release of the pergolide base or
pergolide mesylate is shown in Figures 9 and 10.
CA 02221263 1997-11-17
WO 96/40139 PCT/US96~ )2
28
EXAMPLE 4
The drug/permeation enhancer reservoirs were prepared by mixing
pergolide base or mesylate, EtOH, GML, and caproyl lactic acid (CLA)
5 (R.l.T.A. Corp., Woodstock, IL) as shown in Table 3.
TABLE 3
Drug/Permeation Enhancer Reservoir Composition (weight percent)
Pergolide EtOH GML CLA
(form and cG.Ite~
Base 10 80 10 0
Base 10 90 0 0
Base 10 85 0 5
Mesylate 10 80 10 0
Mesylate 10 90 0 0
Mesylate 10 85 0 5
An additional 3% by weight hydroxypropylcellulose and water were added
10 and the mixture was placed in a suitable container and gelled. A desired
quantity of the mixture was then applied on the surface of a previously
formed trilaminate consisting of a 2 mil thick ethylene vinyl acetate film
having a vinyl acetate content of 18% for use as a rate controlling membrane;
a polyisobutylene contact adhesive containing 2.5% by weight pergolide; and
15 a polyethylene ethylene terephthalate film coated with silicone for use as a
release liner. A Medpar backing was then applied on top of the mixture and
the entire system was heat sealed. The systems were then die-cut to the
required sizes for use in the in vitro test method described in Examples 2 & 3.
The cumulative release of the pergolide base and mesylate are shown in
20 Figures 11 and 12.
CA 02221263 1997-11-17
WO 96/40139 PCT~US~6~0516~2
29
-- EXAMPLE 5
.
A desired quantity of the mixture as formed in Example 4 was then
applied on the surface of a previously formed trilaminate consisting of a 2 mil
5 thick ethylene vinyl acetate film having a vinyl acetate content of 28% for use
as a rate controlling membrane; a polyisobutylene contact adhesive
containing 2.5% by weight pergolide; and a polyethylene ethylene
terephthalate film coated with fluorocarbon for use as a release liner. A
Medpar backing was then applied on top of the mixture and the entire system
10 was heat sealed. The systems were then die-cut to the required sizes for use
in the in vitro test method described in Examples 2-4. The skin flux of the
base and mesylate are shown in Figures 13 and 14.
EXAMPLE 6
The effect of mineral oil on the permeation enhancement of GML with various
cosolvents was studied. The drug/permeation enhancer reservoirs were
prepared by mixing ethylene vinyl acetate having a vinyl acetate conlel)L of
40 percent ("EVA 40", USI Chemicals, Illinois), pergolide mesylate, GML, and
20 a cosolvent selected from Laureth4 (L4) (Heterene Chemical Co., Inc.,
Paterson, N.J.), methyl laurate (Sigma), lauryl lactate (ISP Van Dyk Inc.,
Belleville, NJ) and dodecyl acetate (Penta). The mixture was then dissolved
in tetrahydrofuran. After blending, the mixture was hand cast and dried to a 5
mil. thick film. Various compositions for each cosolvent without mineral oil
25 were compared with a control composition comprising mesylate/GML/laureth-
4/EVA 10/20/12/58. The compositions of the drug reservoirs is shown in
Tables 4a4c.
-
CA 0222l263 l997-ll-l7
WO 96/40139 PCT~S96/09692
TABLE 4a
- Drug/Permeation Enhancer Reservoir Composition (weight percent)
Pergolide mesylate GML Methyl Laurate EVA40
17 3 75
TABLE 4b
Drug/Permeation Enhancer Reservoir Composition (weight percent)
Pergolide mesylate GML Dodecyl Acetate EVA 40
17 3 75
TABLE 4c
Drug/Permeation Enhancer Reservoir Composition (weight percent)
Pergolide mesylate GMLLauryl Lactate EVA40
17 3 75
The film was then laminated to a Medpar backing on one side. The
systems were then die-cut to the required sizes for use in the in vitro test
method described in Examples 2-4. The skin flux of pergolide mesylate is
shown in Figures 15- 17.
Compositions comprising 5% pergolide mesylate, 10% GML, 10% of
one of the lauryl lactate, methyl laurate, or dodecyl acetate cosolvents, 15%
mineral oil, and 60% EVA 40 were then prepared and used in the in vitro skin
flux experiment described above and compared to the pergolide
CA 02221263 1997-11-17
WO 96/40139 PCT/US96/09692
31
mesylate/GML/laureth 4/EVA 40 10/20/12/58 control. The result of the in
vi~ro skin flux experiment is shown in Figure 18. As seen in Figure 18, the
mineral oil had the most substantial effect on the composition comprising
GML and methyl laurate.
Having thus generally described our invention and described certain
specific embodiments thereof, including the embodiments that applicants
consider the best mode of practicing their invention, it should be readily
apparent that various modifications to the invention may be made by workers
skilled in the art without departing from the scope of this invention which is
10 limited only by the following claims.
